

New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Verquvo®

DATE OF MEDICATION REQUEST: / /

SE	CT	ION	I: PA	ATIEN	IT IN	FORM	ЛАТІС	ON A	ND N	1EDI0	CATI	ION	I REQ	UES1	TED											
LAST NAME:								F	FIRST NAME:																	
ME	DI	CAII) ID	NUM	1BER	:								l ∟ D	ATE	OF E	⊥ BIRTH	:							1	
																	_			٦_					1	
GE	ND	ER:				 Male			 □ F	 emal	e e]												_	
Drug Name:									Strength:																	
Do	Dosing Directions:									Length of Therapy:																
SE	CT	ION	II: P	RESC	RIBE	R INF	ORM	ATIC)N																	
LA	LAST NAME:									F	FIRST NAME:															
SP	ECI	ALT'	Y:											N	PI N	UME	BER:									
																									1	
 PH	ON	IE N	UME	BER:										F.	AX N	NUM	BER:								_	
]_]_]_				_				
								<u> </u>						L				<u></u>								
SE	CTI	ION	III: C	CLINI	CALI	HISTC	ORY																			
1.	Does the patient have a diagnosis of heart failure with ejection fraction < 45%?										☐ No															
2.	. Has the patient required use of intravenous (IV) diuretics in the past 3 months?										'es	☐ No														
3.	Has the patient been hospitalized for heart failure in the past 6 months?											'es	☐ No													
4.	ls	Is the patient on guideline-directed therapy for heart failure?																	'es	☐ No						
	Lis	st cu	rren	it the	rapy	or no	ote co	ntra	indica	ation	:															
	Вє	eta-E	Block	ker: _																						
	ΑC	CEi/	ARB:																				_			
																							_			
5.	Is the patient receiving a soluble guanylate cyclase (sGC) stimulator (i.e., riociguat) or a PDE-5 inhibitor									☐ No																
6.	If the patient is of childbearing potential, is the patient using contraception and has pregnancy been Yes N ruled out?									☐ No																





New Hampshire Medicaid Fee-for-Service Program Prior Authorization Drug Approval Form

Verquvo®

DATE OF MEDICATION REQUEST:	/ /
PATIENT LAST NAME:	PATIENT FIRST NAME:
SECTION IV: FOR RENEWALS ONLY	
1. Has the patient demonstrated efficacy (e.g., symptom impr	ovement, slowing of decline)?
2. Has the patient experienced any treatment-limiting adverse	e effects (e.g., symptomatic hypotension)?
Provide any additional information that would help in the decise another page.	ion-making process. If additional space is needed, please use
I certify that the information provided is accurate and comple falsification, omission, or concealment of material fact may su	-
PRESCRIBER'S SIGNATURE.	DATE.

Phone: 1-866-675-7755 **Fax**: 1-888-603-7696

